1. Search Result
Search Result
Results for "

Niemann-Pick disease

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

5

Natural
Products

3

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116815
    Lalistat 1
    2 Publications Verification

    Beta-lactamase Bacterial Infection Neurological Disease
    Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease .
    Lalistat 1
  • HY-113498
    Sphingomyelin
    1 Publications Verification

    Endogenous Metabolite Neurological Disease Metabolic Disease Inflammation/Immunology
    Sphingomyelin is a eukaryotic sphingolipid and one of the major constituents of cell membranes and particularly abundant in the myelin sheath that surrounds neuronal axons. Sphingomyelin plays an important role in cell processes, the regulation of inflammatory responses, and signal transduction. Sphingomyelin metabolism is associated with various central nervous system diseases and Niemann–Pick disease .
    Sphingomyelin
  • HY-59291

    N-Acetyl-L-leucine

    Amino Acid Derivatives Neurological Disease Metabolic Disease Inflammation/Immunology
    Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .
    Levacetylleucine
  • HY-106443A
    Arimoclomol maleate
    5 Publications Verification

    BRX-220

    HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol maleate (BRX-220) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol maleate can be used for the study of Niemann–Pick disease type C.
    Arimoclomol maleate
  • HY-106443
    Arimoclomol
    5 Publications Verification

    BRX-220 free base

    HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol (BRX-220 free base) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system .Arimoclomol can be used for the study of Niemann–Pick disease type C.
    Arimoclomol
  • HY-W754473

    Biochemical Assay Reagents Metabolic Disease
    Lyso-SM-509, a sphingomyelin, is a biomarker for Niemann-Pick disease Type C .
    Lyso-SM-509
  • HY-W778830

    Drug Metabolite Neurological Disease
    Bodipy C12-ceramide (B12Cer) is a fluorescently tagged form of C12-Ceramide (HY-100353) that displays excitation/emission maxima of 505/540 nm, respectively. Bodipy C12-ceramide is formed when acid sphingomyelinase hydrolyzes BODIPY-C12 sphingomyelin in vitro and has been used to quantify acid sphingomyelinase activity in plasma with Niemann-Pick disease .
    Bodipy C12-ceramide
  • HY-N15891

    Endogenous Metabolite Neurological Disease
    Glyco-3ß,5α,6ß -trihydroxycholanoic acid (NPCBA2) is a bile acid which accumulates preferentially in Niemann-Pick C (NPC) patients. Glyco-3ß,5α,6ß -trihydroxycholanoic acid is a biomarker for the early diagnosis of Niemann-Pick C disease .
    Glyco-3ß,5α,6ß -trihydroxycholanoic acid (NPCBA2)
  • HY-W1120833

    Biochemical Assay Reagents Neurological Disease Metabolic Disease
    m-PEG26-NHS ester is a PEG derivative. m-PEG26-NHS ester can be used for the study of Niemann-Pick type C1 disease .
    m-PEG26-NHS ester
  • HY-W414824

    Endogenous Metabolite Neurological Disease
    3β,7β-Dihydroxy-5-cholestenoic acid is a C27 acid that displays elevated levels in Niemann-Pick type C and Niemann-Pick type B diseases, contributing to toxicity in oculomotor neurons. It is synthesized from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) through the enzymatic action of hydroxysteroid 11-β dehydrogenase 1.
    3β,7β-Dihydroxy-5-cholestenoic acid
  • HY-106443B
    Arimoclomol citrate
    5 Publications Verification

    BRX-220 citrate

    HSP Neurological Disease Metabolic Disease Inflammation/Immunology
    Arimoclomol citrate (BRX-220 citrate) is an orally active co-inducer of heat shock proteins (HSP) . Arimoclomol citrate protects motor neurons by enhancing Hsp expression, thus directly affecting protein aggregation and clearance of misfolded assemblies via the proteasome-ubiquitin system . Arimoclomol citrate can be used for the study of Niemann–Pick disease type C.
    Arimoclomol citrate
  • HY-100353

    N-Lauroyl-D-erythro-sphingosine; N-Laurylsphingosine

    Endogenous Metabolite Metabolic Disease Cancer
    C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .
    C12-Ceramide
  • HY-100353R

    N-Lauroyl-D-erythro-sphingosine (Standard); N-Laurylsphingosine (Standard)

    Reference Standards Others Metabolic Disease Cancer
    C12-Ceramide (Standard) is the analytical standard of C12-Ceramide. This product is intended for research and analytical applications. C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .
    C12-Ceramide (Standard)
  • HY-153830

    C16 Lactosylceramide (d18:1/16:0)

    Endogenous Metabolite Neurological Disease Metabolic Disease
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)
  • HY-145549

    N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)

    Endogenous Metabolite Endocrinology
    C20 Sphingomyelin (d18:1/20:0) (N-eicosanoyl-D-erythro-Sphingosylphosphorylcholine; SM(d18:1/20:0)) is a naturally occurring sphingolipid. C20 Sphingomyelin (d18:1/20:0) levels are upregulated in the hippocampus of streptozotocin (HY-13753)-induced diabetic rats and in human plasma, positively correlating with insulin resistance in obese humans. C20 Sphingomyelin (d18:1/20:0) is also upregulated in the liver of a mouse model of Niemann-Pick C1 disease, a neurodegenerative cholesterol sphingolipid lysosomal storage disorder.
    C20 Sphingomyelin (d18:1/20:0)
  • HY-153830S

    C16 Lactosylceramide (d18:1/16:0)-d3

    Isotope-Labeled Compounds Endogenous Metabolite Neurological Disease
    LacCer (d18:1/16:0)-d3 (C16 Lactosylceramide (d18:1/16:0)-d3) is the deuterium labeled LacCer (d18:1/16:0) (HY-153830). LacCer (d18:1/16:0) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)-d3
  • HY-172546

    LysoGM2 ammonium

    PKC Metabolic Disease
    Lyso-monosialoganglioside GM2 (LysoGM2) ammonium is a lysosphingolipid and protein kinase C inhibitor (IC50: 50 μM). Lyso-monosialoganglioside GM2 ammonium can inhibit the binding of protein kinase C to Phorbol 12,13-dibutyrate (HY-18985). Lyso-monosialoganglioside GM2 ammonium is a specific biomarker for GM2 gangliosidosis. Lyso-monosialoganglioside GM2 ammonium can be used in the research of sphingolipidoses .
    Lyso-monosialoganglioside GM2 ammonium
  • HY-131682

    3-Hexanoyl-NBD-cholesterol

    Fluorescent Dye Others
    3-C6-NBD-cholesterol is a fluorescent analog of Chol that can be used to measure the kinetics of membrane and intracellular trafficking .
    3-C6-NBD-cholesterol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: